https://www.selleckchem.com/products/ars-853.html
her two treatment groups. Median overall survival has not been reached in any of the groups. There are clear differences in activity and toxicity of the three combination regimens. The tolerability and preliminary activity for the two most active regimens, brentuximab vedotin with nivolumab and the triplet therapy, are being compared in a randomised phase 2 trial (NCT01896999). Eastern Cooperative Oncology Group-American College of Radiology Imaging Network and the National Cancer Institute of the National Institutes of Health. Eastern
Like
Comment
Share
